I would assume that the investor who accumulated 200 mil shares...

I would assume that the investor who accumulated 200 mil shares regarded a 15 cents entry level as cheap. What followed later might be more short term related and motivated’ sophisticated’ investors who are expecting 400 to 500% profit margins within. 8 months of investment, hence the aggressive price control. You have seen such positioning on another stock 2.5 years ago, I would expect similar outcomes if data comes in as expected and platform extension being published. What is the real caveat is the stealth research combined with the promised publication of the same end of this year. If one reveals the kidney/CNS candidates, certain partner connections might be forced to be revealed as well, why else fly stealth for a year and endure 60 % share prices? One feels reminded of Voyager whose price was reduced by the exact same percentage amount before Pfizer committed to an extensive license deal, all IMO